Episode Details

A large U.S. study found no evidence that taking Ozempic or Wegovy is tied to an increase in suicidal thoughts, researchers reported recently. 

研究人员最近报道说，一项大型美国研究没有发现证据表明服用Ozempic或Wegovy与自杀思想的增加有关。 

Both Ozempic for type 2 diabetes and the obesity treatment Wegovy have the same active ingredient, semaglutide. 

用于2型糖尿病的Ozempic和肥胖治疗Wegovy具有相同的活性成分，semaglutide。

The analysis included electronic medical record data from more than 1.8 million patients. Researchers actually found a lower risk of new and recurring suicidal thoughts in those taking semaglutide compared to those using other medications for weight loss or diabetes. 

该分析包括来自180万患者的电子病历数据。 研究人员实际上发现，与使用其他药物减肥或糖尿病的药物相比，在服用半卢替肽的人中，新的和反复出现的自杀思想的风险较低。 

Semaglutide belongs to a class of drugs known as GLP-1 agonists, which were designed to treat type 2 diabetes. In addition to helping control blood sugar levels, the drugs produce a feeling of fullness. 

半卢宾属于一类称为GLP-1激动剂的药物，这些药物旨在治疗2型糖尿病。 除了帮助控制血糖水平外，这些药物还会产生一种饱满感。 

Concerns over reports of suicidal ideation connected with semaglutide led to an investigation by the European Medicines Agency. The U.S. Food and Drug Administration (FDA) has listed suicidal ideation as a possible safety concern for GLP-1 drugs. 

人们对与Semaglutide有关的自杀念头的报道的担忧导致了欧洲药品局的调查。 美国食品药品监督管理局（FDA）已将自杀意念列为GLP-1药物的安全问题。 

A Reuters examination last year found that the FDA had received 265 reports of suicidal thoughts or behavior in patients taking semaglutide or similar medicines since 2010. Thirty-six of those reports describe a death by suicide or suspected suicide. 

路透检查员去年的一项检查发现，自2010年以来，FDA收到了265例服用Semaglutide或类似药物的患者的自杀念头或行为的报告。这些报告中有36例描述了自杀或怀疑自杀的死亡。 

Listen Now